PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy

Biomaterials

Volumn 35, Issue 28, 2014, Pages 8215-8226

  Gu, Guangzhi ^a,c   Hu, Quanyin ^a   Feng, Xingye ^a   Gao, Xiaoling ^b   Menglin, Jiang ^a   Kang, Ting ^a   Jiang, Di ^a   Song, Qingxiang ^b   Chen, Hongzhuan ^b   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE FOR FOOD AND DRUG CONTROL   (China)

Author keywords

APTEDB peptide; Dual targeting; Glioma therapy; Nanoparticles; Paclitaxel

Indexed keywords

CHEMOTHERAPY; CYTOLOGY; ENDOTHELIAL CELLS; ENZYME INHIBITION; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES;

ANTI-ANGIOGENIC THERAPY; CELLULAR INTERNALIZATION; DUAL-TARGETING; FIBRONECTIN EXTRA DOMAINS; GLIOMA THERAPY; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; INTRAVENOUS ADMINISTRATION; PACLITAXEL;

TUMORS;

APTEDB PEPTIDE; MATRIGEL; NANOPARTICLE; PACLITAXEL; PEPTIDE DERIVATIVE; POLY(ETHYLENE GLYCOL) POLY(LACTIC ACID) NANOPARTICLE; POLYMER; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; APT(EDB) PEPTIDE; COLLAGEN; DRUG COMBINATION; LAMININ; MACROGOL DERIVATIVE; MONOMETHOXYPOLYETHYLENEGLYCOL-POLYLACTIDE BLOCK COPOLYMER; PEPTIDE; PROTEOGLYCAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPID RAFT; MALE; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; BAGG ALBINO MOUSE; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; CAVEOLA; CELL MEMBRANE; CELL PROLIFERATION; CHEMISTRY; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; NUDE MOUSE; PROTEIN TERTIARY STRUCTURE; TEMPERATURE; TUMOR CELL LINE;

ANIMALIA;

ADMINISTRATION, INTRAVENOUS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CAVEOLAE; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ENDOCYTOSIS; FEMALE; GLIOMA; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LAMININ; MEMBRANE MICRODOMAINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PACLITAXEL; PARTICLE SIZE; PEPTIDES; POLYETHYLENE GLYCOLS; PROTEIN STRUCTURE, TERTIARY; PROTEOGLYCANS; TEMPERATURE;

EID: 84903721641     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.06.022     Document Type: Article

References (45)

1. Remer S., Murphy M.E. The challenges of long-term treatment outcomes in adults with malignant gliomas. Clin J Oncol Nurs 2004, 8:368-376.
2. Chamberlain M. Evolving strategies: future treatment of glioblastoma. Expert Rev Neurother 2011, 11:519-532.
3. Hu Q., Gu G., Liu Z., Jiang M., Kang T., Miao D., et al. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials 2013, 34:1135-1145.
4. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
5. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 2011, 17:1359-1370.
6. Khasraw M., Ameratunga M., Grommes C. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opin Biol Ther 2014, 14:729-740.
7. Neri D., Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5:436-446.
8. Liu C., Zhang N. Emerging biotechnological strategies for non-viral antiangiogenic gene therapy. Angiogenesis 2012, 15:521-542.
9. Gordon M.S., Mendelson D.S., Kato G. Tumor angiogenesis and novel antiangiogenic strategies. Int J Cancer 2010, 126:1777-1787.
10. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
11. Hu Q., Gao X., Kang T., Feng X., Jiang D., Tu Y., et al. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels. Biomaterials 2013, 34:9496-9508.
12. Zhang B., Wang H., Liao Z., Wang Y., Hu Y., Yang J., et al. EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma. Biomaterials 2014, 35:4133-4145.
13. Rybak J.N., Trachsel E., Scheuermann J., Neri D. Ligand-based vascular targeting of disease. Chemmedchem 2007, 2:22-40.
14. Tarli L., Balza E., Viti F., Borsi L., Castellani P., Berndorff D., et al. A high-affinity human antibody that targets tumoral blood vessels. Blood 1999, 94:192-198.
15. Nilsson F., Kosmehl H., Zardi L., Neri D. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 2001, 61:711-716.
16. Santimaria M., Moscatelli G., Viale G.L., Giovannoni L., Neri G., Viti F., et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res 2003, 9:571-579.
17. Mariani G., Lasku A., Balza E., Gaggero B., Motta C., Di Luca L., et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 1997, 80:2378-2384.
18. Sauer S., Erba P.A., Petrini M., Menrad A., Giovannoni L., Grana C., et al. Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients. Blood 2009, 113:2265-2274.
19. Kim S., Kim D., Jung H.H., Lee I.H., Kim J.I., Suh J.Y., et al. Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew Chem Int Ed Engl 2012, 51:1890-1894.
20. Saw P.E., Kim S., Lee I.H., Park J., Yu M., Lee J.J., et al. Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy. J Mater Chem B 2013, 1:4723-4726.
21. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
22. Hu Q., Gao X., Gu G., Kang T., Tu Y., Liu Z., et al. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel. Biomaterials 2013, 34:5640-5650.
23. Xia H., Gao X., Gu G., Liu Z., Hu Q., Tu Y., et al. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery. Int J Pharm 2012, 436:840-850.
24. Xia H., Gao X., Gu G., Liu Z., Zeng N., Hu Q., et al. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration. Biomaterials 2011, 32:9888-9898.
25. Gu G., Xia H., Hu Q., Liu Z., Jiang M., Kang T., et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials 2013, 34:196-208.
26. Kang T., Gao X., Hu Q., Jiang D., Feng X., Zhang X., et al. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas. Biomaterials 2014, 35:4319-4332.
27. Zeng N., Gao X., Hu Q., Song Q., Xia H., Liu Z., et al. Lipid-based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water-soluble drugs: cellular interaction and in vivo absorption. Int J Nanomed 2012, 7:3703-3718.
28. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
29. Christian S., Pilch J., Akerman M.E., Porkka K., Laakkonen P., Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163:871-878.
30. Jiang X., Xin H., Gu J., Xu X., Xia W., Chen S., et al. Solid tumor penetration by integrin-mediated pegylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials 2013, 34:1739-1746.
31. Kavitha C.V., Agarwal C., Agarwal R., Deep G. Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. PLoS One 2011, 6:e22745.
32. Kim J.Y., Shim G., Choi H.W., Park J., Chung S.W., Kim S., et al. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials 2012, 33:4424-4430.
33. Morales A.R., Yanez C.O., Zhang Y., Wang X., Biswas S., Urakami T., et al. Small molecule fluorophore and copolymer RGD peptide conjugates for ex vivo two-photon fluorescence tumor vasculature imaging. Biomaterials 2012, 33:8477-8485.
34. Luo L.M., Huang Y., Zhao B.X., Zhao X., Duan Y., Du R., et al. Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel. Biomaterials 2013, 34:1102-1114.
35. Yu D.H., Ban F.Q., Zhao M., Lu Q., Lovell J.F., Bai F., et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials 2013, 34:3925-3937.
36. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
37. Cheng Z., Al Zaki A., Hui J.Z., Muzykantov V.R., Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012, 338:903-910.
38. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006, 118:1331-1339.
39. Guo J., Gao X., Su L., Xia H., Gu G., Pang Z., et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 2011, 32:8010-8020.
40. Gu G., Gao X., Hu Q., Kang T., Liu Z., Jiang M., et al. The influence of the penetrating peptide iRGD on the effect of paclitaxel-loaded MT1-AF7p-conjugated nanoparticles on glioma cells. Biomaterials 2013, 34:5138-5148.
41. Aoki T., Nomura R., Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 1999, 253:629-636.
42. Mo Y., Lim L.Y. Mechanistic study of the uptake of wheat germ agglutinin-conjugated PLGA nanoparticles by A549 cells. J Pharm Sci 2004, 93:20-28.
43. Vercauteren D., Vandenbroucke R.E., Jones A.T., Rejman J., Demeester J., De Smedt S.C., et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther 2010, 18:561-569.
44. Jiang S., Rhee S.W., Gleeson P.A., Storrie B. Capacity of the golgi apparatus for cargo transport prior to complete assembly. Mol Biol Cell 2006, 17:4105-4117.
45. Akhtar N., Dickerson E.B., Auerbach R. The sponge/Matrigel angiogenesis assay. Angiogenesis 2002, 5:75-80.